Socio-demographic
|
Female sex1
|
55 (98.2)
|
332 (92.5)
|
0.152
|
Years of age
|
58.5 (46.4–63)
|
54.7 (44.8–60.7)
|
0.082
|
Years of formal education
|
9 (6–14.8)
|
9 (6–13)
|
0.372
|
Medium-low SE level1
|
53 (94.6)
|
335 (93.3)
|
1
|
RA-related
|
Serum positive RF1
|
48 (85.7)
|
325 (90.5)
|
0.337
|
Serum positive ACCP1
|
49 (87.5)
|
324 (90.3)
|
0.481
|
Years of disease duration
|
14 (8.3–20.3)
|
13.2 (7.7–18.3)
|
0.224
|
Rheumatoid nodes1
|
28 (50)
|
67 (18.7)
|
≤ 0.0001
|
RAPID-3
|
10.8 (2–18)
|
4.2 (1.6–10)
|
0.004
|
High disease activity category1
|
25 (44.6)
|
71 (19.8)
|
≤ 0.0001
|
Patient-reported outcomes
|
Pain-VAS
|
9.8 (5–31)
|
5 (2–16)
|
≤ 0.0001
|
Overall disease-VAS
|
10 (5–35)
|
5 (1–18)
|
0.001
|
HAQ score
|
1 (0–2.1)
|
0.25 (0–1.1)
|
0.001
|
SF-36 score
|
61.3 (41.1–81.1)
|
73 (54.3–87)
|
0.002
|
Mental component score (SF-36)
|
62.5 (42.9–86.9)
|
76.6 (56.9–88.4)
|
0.008
|
Physical component score (SF-36)
|
55.3 (38–80)
|
70.4 (51.4–87.8)
|
0.003
|
Comorbidity
|
Presence of comorbidity1
|
38 (67.9)
|
217 (60.4)
|
0.306
|
Surgical joint replacement1
|
22 (39.3)
|
65 (18.1)
|
0.001
|
Treatment
|
DMARDs/patient
|
1 (1–2)
|
1 (1–2)
|
0.031
|
Corticosteroids use1
|
29 (51.8)
|
153 (42.6)
|
0.247
|
Intensive treatment1
|
28 (50)
|
144 (40.1)
|
0.190
|
Compliance with treatment
|
Adherence1
|
29 (51.8)
|
199 (55.4)
|
0.666
|
Persistence1
|
30 (53.6)
|
197 (54.9)
|
0.886
|
Concordance1
|
25 (44.6)
|
158 (44)
|
1
|
Miscellaneous
|
Health Literacy1
|
46 (82.1)
|
283 (78.8)
|
0.723
|
Adequate RA knowledge1 (based on CQ)
|
25 (44.6)
|
170 (47.4)
|
0.774
|
RA family history1
|
28 (50)
|
158 (44)
|
0.470
|
Significant RP1
|
32 (57.1)
|
62 (17.3)
|
≤ 0.0001
|
Unfavorable medical criteria
|
6 (5–7)
|
5 (4–6)
|
≤ 0.0001
|